USL311 is a selective CXCR4 antagonist, with anti-tumor activity. USL311 prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4[1].

NBI-74330 is a small molecule antagonist for CXCR3, NBI-74330 demonstrates potent inhibition of [(125)I]CXCL10 and [(125)I]CXCL11 specific binding (K (i) of 1.5 and 3.2 nM, respectively.

SRT3109 is a CXCR2 ligand for use in the treatment of chemokine mediated diseases and conditions.

UNBS5162 is a naphthalimide and a hydrolysis product of UNBS3157 that decreases CXCL chemokine expression in experimental prostate cancers and the mean antiproliferative activity IC50 value is 17.9 μM for 9 cancer cell lines.

ITIC-4F是基于茚并二噻吩并噻吩 (IDTT) 的后富勒烯电子受体，用于高效二元和三元单结以及串联聚合物太阳能电池中，广泛用于有机光伏研究。

Baohuoside I, a flavonoid, acts as an apoptosis inducer and a down-regulator of durvivin and cyclin D1 expression. It is used as an anti-cancer agent and can be isolated and purified from the roots of epimedium brevicornu Maxim.

PS372424 HCl是 CXCL10 的三个氨基酸片段，作为特异性 CXCR3 激动剂，具有抗炎活性。在关节炎模型中，PS372424 hydrochloride 抑制 T 细胞迁移，适用于炎症和免疫相关疾病的研究。

CXCR2 antagonist 8是一种高效的选择性 CXCR2 拮抗剂，展示了在胰岛素抵抗研究中的潜在应用。

VUF11207 fumarate是一种CXCR7激动剂，能够与CXCR7特异性结合。它能通过抑制ERK的磷酸化减少CXCL12介导的破骨细胞生成和骨吸收。

LIT-927 是局部的、有口服活性的 CXC 趋化因子12 (CXCL12) 的中性配体，具有抗炎作用，对 CXCL12 结合到其受体 CXCR4 的 Ki 值为 267 nM。

JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM.

MSX-122 是一种口服可用的部分 CXCR4 拮抗剂，抑制 CXCR4/CXCL12 相互作用的 IC50 约为 10 nM。MSX-122 具有抗炎和抗转移活性。

SB225002 is a potent and selective non-peptide inhibitor of CXCR2 with IC50 of 22 nM, showing > 150-fold selectivity over CXCR1 and four other 7-TMRs.

AMD 3465 hexahydrobromide is a potent, selective CXCR4 antagonist and exhibits 8-fold higher affinity than AMD 3100 and inhibits SDF-1α-ligand binding (Ki = 41.7 nM).

Decursin ((+)-Decursin) 是一种有效的抗癌剂，具有细胞毒性和强效激活蛋白激酶 C (PKC) 的作用。Decursin 诱导细胞凋亡和 G1 期细胞周期停滞。Decursin 在 48 小时内减少 CDK2、CDK4、CDK6 和 cyclin D1 蛋白的表达。Decursin 抑制细胞增殖和迁移，具有抗肿瘤、抗炎和镇痛活性。

AZD 5069 is a selective and reversible antagonist of CXCR2 that can inhibit CXCL8 binding to CXCR2 with pIC50 of 9.1.

AZD8797（KAND567）是一种别构、非竞争性、口服有效的人CX3CR1受体拮抗剂，对CX3CR1和CXCR2的Ki值分别为3.9 nM和2800 nM。

Plerixafor octaHCl 是一种 CXCR4 拮抗剂，能够动员造血干细胞。Plerixafor octaHCl 主要用于干细胞移植和 HIV 感染的研究。

SB-265610 is a potent CXCR2 antagonist that inhibits CINC-1-mediated but not C5a-mediated Ca2+ mobilization (IC50 values are 3.4 and 6800 nM respectively). It inhibits CINC-induced chemotaxis and attenuates neutrophil accumulation in inflammatory lung injury in vivo.

ZK756326 is a full agonist of CCR8（Chemokine receptor 8） with an IC50 of 1.8 μM, dose-responsively eliciting an increase in intracellular calcium and cross-desensitizing the response of the receptor to CCL1.